Non-Lysosomal Glucosylceramidase Inhibitors, Alectos Therapeutics, Granted Apr 28
Summary
The USPTO granted Patent US12612380B2 to Alectos Therapeutics 1NC on April 28, 2026, covering non-lysosomal glucosylceramidase inhibitors, prodrugs thereof, and pharmaceutical compositions for inhibiting glucosylceramidases. The application was filed May 7, 2020 (Application No. 17594834) and includes 27 claims across multiple C07D organic chemistry classifications. The patent provides intellectual property protection for novel compounds and their therapeutic uses.
“The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.”
About this source
Granted patents in USPTO classification C07D, covering heterocyclic organic compounds: the chemical core of most small-molecule drugs. Around 160 grants a month. Unlike applications, grants are enforceable. This feed is the best public-domain signal of which small-molecule compositions have just become defensible IP, which matters for generic entry timing, freedom-to-operate opinions, and competitive intelligence. Watch this if you practice pharma IP law, manage a drug discovery patent portfolio, advise on compound licensing, or scout ANDA opportunities as brand drugs approach loss of exclusivity. Recent grants cover apalutamide process improvements and bioactive phenolate ionic complexes.
What changed
The USPTO issued Patent US12612380B2 to Alectos Therapeutics 1NC, conferring exclusivity rights for non-lysosomal glucosylceramidase inhibitor compounds, their prodrugs, and related pharmaceutical compositions through the patent's term. The patent names six inventors and covers multiple CPC classifications within organic chemistry (C07D), reflecting a broad scope of chemical compound claims.
For parties developing competing glucosylceramidase inhibitors or seeking to license this technology, the granted patent establishes a protected intellectual property landscape. Pharmaceutical researchers and drug developers targeting this enzyme class should conduct freedom-to-operate analyses and consider design-around strategies or licensing negotiations with Alectos Therapeutics.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Non-lysosomal glucosylceramidase inhibitors and uses thereof
Grant US12612380B2 Kind: B2 Apr 28, 2026
Assignee
ALECTOS THERAPEUTICS 1NC
Inventors
Ramesh Kaul, Ernest J. Mceachern, Jianyu Sun, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu
Abstract
The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
CPC Classifications
C07D 401/06 C07D 211/32 C07D 211/46 C07D 401/14 C07D 405/06 C07D 405/10 C07D 409/06 C07D 409/14 C07D 413/14 C07D 417/14
Filing Date
2020-05-07
Application No.
17594834
Claims
27
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.